The license agreement with Hefei Co-source Biomedical Co. for the development and commercialisation in China of PAT-SC1 is ongoing and progressing to plan. The Joint Development Committee for the alliance has met twice, most recently in Q4, 2017. It is pleasing to note that this relationship is building into a constructive partnership with the potential for further value enhancement.
Sorry to be so excited here folks but this one above is a stunner. Potential is amazing and after todays positive cancer news, anything is possible. These guys now appear to be at the next stage, and I have to say that the ceo seems matter of fact as well. All good signs, and nice tie ups with the right professional organizations. This will surely hit the news on Yale television I am sure.
Ann: PAT-DX1 is synergistic with PARP inhibitor, page-8
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.001(33.3%) |
Mkt cap ! $8.229M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $3.293K | 1.023M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 35 | 28067181 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 25555973 | 16 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |